# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN-TD
- Date: 1885-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests. **S**

## Objective

Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 24 mmol/L; BUN: 21 mg/dL; Creatinine: 1.2 mg/dL (high); eGFR: 54 mL/min/1.73 m² (low); Glucose: 92 mg/dL; Calcium: 9.3 mg/dL; Phosphate: 3.8 mg/dL; Intact PTH: 74 pg/mL (high); 25-hydroxyvitamin D: 21 ng/mL (low); Albumin: 4.1 g/dL; Hemoglobin: 12.3 g/dL; Total cholesterol: 214 mg/dL (high); HDL cholesterol: 54 mg/dL; LDL cholesterol: 134 mg/dL (high); Triglycerides: 130 mg/dL; HbA1c: 5.5%; TSH: 2.1 mIU/L; Urine albumin-creatinine ratio: 240 mg/g (high); Urine red cells: 1 /[HPF]; KFRE 2-year kidney failure risk: 0.5%; KFRE 5-year kidney failure risk: 1.6%; PHQ-9: 6; GAD-7: 5. All results are synthetic.

BP 166/98 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 54 kg; BMI 20.3 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate; Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension; Vitamin D deficiency with a mildly raised PTH in chronic kidney disease. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Stopped: Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) **S**
- Started: Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Started: Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily **S**
- Started: Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**

## Plan

- Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percent. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks later. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFR. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Nephrology consultation to confirm the cause of chronic kidney disease with albuminuria in a woman in her fifties and to advise on treatment and follow-up. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearly. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTH. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccines. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026); Adult Immunization Schedule by Age (2026) **S**
- Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointment. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
- PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairment. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026); Anxiety Disorders in Adults: Screening (2023); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walking. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026) **S**
